

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1395PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 00/ 26442</b>	International filing date (day/month/year) <b>27/09/2000</b>	(Earliest) Priority Date (day/month/year) <b>30/09/1999</b>
Applicant  <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**GENES ENCODING STEROL DELTA-14 REDUCTASE IN PLANTS**

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1  
☐ None of the figures.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26 partially

Polynucleotide encoding a polypeptide of at least 126 amino acids having a sequence identity of at least 50%, 85%, 90% or 95% to SEQID2 or encoding a polypeptide of at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 4 and 8; the polynucleotide comprising the nucleotide sequences of SEQIDs 1,3 or 7; a nucleic acid molecule hybridizing to said polynucleotides; the recombinant expression of the same in host cells; a method for transforming a cell with said polynucleotides; a method for producing a transgenic plant by transforming the plant with said polynucleotides; an isolated polypeptide of at least 126 amino acids having a sequence identity of at least 50%, 85%, 90% or 95% to SEQID2 or encoding a polypeptide of at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 4 and 8; a method for altering the level of sterol delta-14 reductase expression in a host cell by transforming the cell with said polynucleotides.

2. Claims: 1-26 partially

Polynucleotide encoding a polypeptide of at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 6; the polynucleotide comprising the nucleotide sequence of SEQIDs 5; a nucleic acid molecule hybridizing to said polynucleotide; the recombinant expression of the same in host cells; a method for transforming a cell with said polynucleotide; a method for producing a transgenic plant by transforming the plant with said polynucleotide; an isolated polypeptide at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 6; a method for altering the level of sterol delta-14 reductase expression in a host cell by transforming the cell with said polynucleotide.



## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claim 8 was read as referring to a polypeptide that is a sterol delta-14 reductase.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



## INTERNATIONAL SEARCH REPORT

International Application No

PC 00/26442

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N15/53 C12N9/02 C12N5/10 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, WPI Data, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 48793 A (GEN HOSPITAL CORP) 24 December 1997 (1997-12-24) the whole document ---	1-26
A	EP 0 644 268 A (AMERICAN CYANAMID CO) 22 March 1995 (1995-03-22) the whole document ---	
A	WO 98 45457 A (MONSANTO CO) 15 October 1998 (1998-10-15) page 9 --- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

9 May 2001

Date of mailing of the international search report

25/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S





## INTERNATIONAL SEARCH REPORT

International Application No

PC 00/26442

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SCHRICK KATHRIN ET AL: "FACKEL is a sterol C-14 reductase required for organized cell division and expansion in Arabidopsis embryogenesis." GENES & DEVELOPMENT, vol. 14, no. 12, 15 June 2000 (2000-06-15), pages 1471-1484, XP002166945 ISSN: 0890-9369 the whole document ----	10
P,X	JANG JYAN-CHYUN ET AL: "A critical role of sterols in embryonic patterning and meristem programming revealed by the fackel mutants of Arabidopsis thaliana." GENES & DEVELOPMENT, vol. 14, no. 12, 15 June 2000 (2000-06-15), pages 1485-1497, XP002166946 ISSN: 0890-9369 the whole document -----	10



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/SG 00/26442

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9748793 A	24-12-1997	AU 3493997 A EP 0954568 A	07-01-1998 10-11-1999
EP 0644268 A	22-03-1995	US 5591576 A	07-01-1997
WO 9845457 A	15-10-1998	AU 724046 B AU 5709998 A BR 9714439 A CN 1247569 A EP 0958370 A	07-09-2000 30-10-1998 21-03-2000 15-03-2000 24-11-1999



# PATENT COOPERATION TREATY

**PCT**

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 13 June 2001 (13.06.01)	<b>Applicant's or agent's file reference</b> BB1395PCT
<b>International application No.</b> PCT/US00/26442	<b>Priority date (day/month/year)</b> 30 September 1999 (30.09.99)
<b>International filing date (day/month/year)</b> 27 September 2000 (27.09.00)	
<b>Applicant</b> FAMODU, Omolayo, O. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

12 April 2001 (12.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colmbettes 1211 Genève 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer Olivia TEFY</p> <p>Telephone No.: (41-22) 338.83.38</p>
---	---



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

12

Applicant's or agent's file reference BB1395PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/26442	International filing date (day/month/year) 27/09/2000	Priority date (day/month/year) 30/09/1999
International Patent Classification (IPC) or national classification and IPC C12N15/00		
Applicant E.I. DU PONT DE NEMOURS AND COMPANY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 12/04/2001	Date of completion of this report 18.12.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Armandola, E Telephone No. +49 89 2399 7493 





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/26442

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-32 as originally filed

**Claims, No.:**

1-26 as originally filed

**Drawings, sheets:**

1/2-2/2 as originally filed

**Sequence listing part of the description, pages:**

1-9, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/26442

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.  
☐ paid additional fees.  
☐ paid additional fees under protest.  
☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.  
☐ not complied with for the following reasons:

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☒ all parts.  
☐ the parts relating to claims Nos. .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N) Yes: Claims



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/26442

---

	No:	Claims	1, 8-18, 23-25
Inventive step (IS)	Yes:	Claims	
	No:	Claims	2-7, 19-22, 26
Industrial applicability (IA)	Yes:	Claims	1-26
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/26442

**Re Item IV**

**Lack of unity of invention**

The IPEA agrees with the objection made by the International Search Authority about the lack of unity of the present application. The reasons for the lack of unity are as follows:

polynucleotides encoding plant sterol reductases and their uses were known (see WO9748793). The problem to be solved by the present application can be seen as the provision of further polypeptides encoding sterol reductases. The only common special technical features shared by the provided solutions (polynucleotides and polypeptides identified by SEQ. ID. NO: 1-8) is their belonging to the sterol reductase class of enzymes. These enzymes were, however, known. Therefore, no single general inventive concept (Rule 13.1 PCT) can be recognized as linking the claimed proteins.

However, as the ISA has provided a complete search report, the IPEA has decided not to invite the applicant to pay additional fees and to carry out the examination for all inventions.

The objection to lack of unity will, however, be prosecuted during regional phase examination at the EPO.

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document:

D1: WO 97 48793 A (GEN HOSPITAL CORP) 24 December 1997 (1997-12-24)

Novelty and Inventive step (Art. 33(2) (3) PCT)

i) Claims 1, 8-18 and 23-25 cannot be considered novel in view of document D1 which discloses plant sterol reductases and their uses. In particular SEQ. ID. NO: 2 of D1 displays 64.3% identity to SEQ. ID. NO: 2 of the application. Cells containing the polynucleotide encoding the C-14 sterol reductase, methods of transforming cells, isolating the C-14 sterol reductase and of producing transgenic plants containing constructs





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/26442

encoding it are also disclosed, as well as methods of altering the levels of the enzyme in plants.

It should be noted that even if novelty were re-established by increasing the percent identity required in claim 1 a), the claims would not be considered inventive. The problem to be solved by the present claims could be seen as that of providing an alternative C-14 sterol reductase (namely one derived from another plant species); as D1 provides an incentive and the means for doing this (see e.g. claim 25), the skilled person would not have needed to exercise inventive skill to obtain such an additional C-14 sterol reductase. For the same reasons claims 2-7, 19-22 and 26 cannot be considered inventive.

**Re Item VII**

**Certain defects in the international application**

Claim 8 is incomplete.

**Re Item VIII**

**Certain observations on the international application**

Clarity (Art. 6 PCT)

i) Claims 1-4 and 18-21 contain the indication of a percent identity that the claimed polynucleotide should display, but no functional feature is given which may identify the polynucleotide precisely. Polynucleotides which do not encode a protein according to the invention might also fall under the scope of the claims. The claims are, therefore considered unclear.

ii) In claim 6 a fragment is claimed for which no functional limitation is given. The claim is considered to be vague and unclear as it leaves the reader in doubt as to how the fragment of 125 nucleotides should be chosen within the SEQ. ID. NO. indicated.



## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N15/53 C12N9/02 C12N5/10 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, WPI Data, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 48793 A (GEN HOSPITAL CORP) 24 December 1997 (1997-12-24) the whole document ---	1-26
A	EP 0 644 268 A (AMERICAN CYANAMID CO) 22 March 1995 (1995-03-22) the whole document ---	
A	WO 98 45457 A (MONSANTO CO) 15 October 1998 (1998-10-15) page 9 --- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

9 May 2001

Date of mailing of the international search report

25/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

11.

[illegible]

1

1  
2  
3  
4  
5  
6  
7  
8  
9



## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SCHRICK KATHRIN ET AL: "FACKEL is a sterol C-14 reductase required for organized cell division and expansion in Arabidopsis embryogenesis." GENES & DEVELOPMENT, vol. 14, no. 12, 15 June 2000 (2000-06-15), pages 1471-1484, XP002166945 ISSN: 0890-9369 the whole document ---	10
P,X	JANG JYAN-CHYUN ET AL: "A critical role of sterols in embryonic patterning and meristem programming revealed by the fackel mutants of Arabidopsis thaliana." GENES & DEVELOPMENT, vol. 14, no. 12, 15 June 2000 (2000-06-15), pages 1485-1497, XP002166946 ISSN: 0890-9369 the whole document -----	10




Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9748793	A	24-12-1997	AU	3493997 A	07-01-1998
			EP	0954568 A	10-11-1999
-----					
EP 0644268	A	22-03-1995	US	5591576 A	07-01-1997
-----					
WO 9845457	A	15-10-1998	AU	724046 B	07-09-2000
			AU	5709998 A	30-10-1998
			BR	9714439 A	21-03-2000
			CN	1247569 A	15-03-2000
			EP	0958370 A	24-11-1999
-----					

...the ... of ...  
...the ... of ...  
...the ... of ...

...the ... of ...  
...the ... of ...  
...the ... of ...

...the ... of ...  
...the ... of ...  
...the ... of ...





## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

on July 31, 2002  
Date

Susan L. Durkee  
Signature

SUSAN L. DURKEE  
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

10/069,427  
BB1395 US PCT  
INFORMATION DISCLOSURE STATEMENT  
SB08B FORMS - 2 PAGES  
REFERENCES  
POSTCARD  
SB08A FORM - 1 PAGE  
COPY OF INTERNATIONAL SEARCH REPORT

1974-1975

1976-1977

1978-1979

1980-1981

1982-1983

1984-1985

1986-1987

1988-1989

1990

1991-1992

1993-1994

1995-1996

1997-1998

1999-2000

2001-2002

2003

2004-2005

2006-2007

2008-2009

2010-2011

2012-2013

2014-2015

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
WO 01/23539 A2(51) International Patent Classification<sup>7</sup>: C12N 15/00

19702 (US). KINNEY, Anthony, J. [GB/US]; 609 Lore Avenue, Wilmington, DE 19809 (US).

(21) International Application Number: PCT/US00/26442

(22) International Filing Date:  
27 September 2000 (27.09.2000)

(74) Agent: LI, Kening; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/156,820 30 September 1999 (30.09.1999) US

(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.

(72) Inventors; and

(75) Inventors/Applicants (for US only): FAMODU, Omo-layo, O. [US/US]; 216 Barrett Run Place, Newark, DE

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: GENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS

Comparison of the Corn, Soybean (2), and Arabidopsis Sterol Delta-14 Reductases

p0097.cqrau67ra\_fis.PRO -----  
 src3c.pk009.c1\_fis.PRO M-----MESHVDLGFLLOALTPSWNSVPLLVG-----  
 sm.pk0031.d12\_fis.PRO M-----MESHVDLGFLLOALTPSWNSVPLLVG-----  
 8917585\_(Arabidopsis).PRO M-----DLGVLLPSL-----QSVTVLVF-----

p0097.cqrau67ra\_fis.PRO -----PRVR-----KMKVELSLLSGLANLC-----  
 src3c.pk009.c1\_fis.PRO -----FTTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA-----  
 sm.pk0031.d12\_fis.PRO -----FTTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA-----  
 8917585\_(Arabidopsis).PRO -----YFVYLAVAGEILPGKVIKGVLLSDGSOLRYRONGLLALILLVAILGICA-----

p0097.cqrau67ra\_fis.PRO -----  
 src3c.pk009.c1\_fis.PRO KMGFVSPT-----AISDRGLELLSTTFAPSFLVTLILHFSGCKSQSKGSS--LKPH-LSG  
 sm.pk0031.d12\_fis.PRO KMGFVSPT-----AISDRGLELLSTTFAPSFLVTLILHFSGCKSQSKGSS--LKPH-LSG  
 8917585\_(Arabidopsis).PRO KLGIVSPL-----VVADRGLELLSATFIICVLVTLALVYTGSSSNKGSS--LKPH-VSG

p0097.cqrau67ra\_fis.PRO -----  
 src3c.pk009.c1\_fis.PRO NLIRDMWFGIQLNPQFMG-IDLKFTF-VRAGMGWLLINLSILAKSIO-DGTLSSQMILY  
 sm.pk0031.d12\_fis.PRO NLIRDMWFGIQLNPQFMG-IDLK-----AGMGWLLINLSILAKSIO-DGTLSSQMILY  
 8917585\_(Arabidopsis).PRO NLIRDMWFGIQLNPQFMG-IDLKFTF-VRAGMGWLLINLSILAKSIO-DGTLSSQMILY

p0097.cqrau67ra\_fis.PRO -----  
 src3c.pk009.c1\_fis.PRO QLFALYILDYFVREEYMTSTWDIIAERLGFMLVFGDLVWIPFSSIQGWWLLHNSVELT  
 sm.pk0031.d12\_fis.PRO QLFALYILDYFVREEYMTSTWDIIAERLGFMLVFGDLVWIPFSSIQGWWLLHNSVELT  
 8917585\_(Arabidopsis).PRO QLFALYILDYFVREEYMTSTWDIIAERLGFMLVFGDLVWIPFSSIQGWWLLHNSVELT

p0097.cqrau67ra\_fis.PRO -----IFLIGYLVFRGANKQKHVFKQPKAPINGKPKV-----GGKLLASGYNGIA  
 src3c.pk009.c1\_fis.PRO PAALVANCFTVLIGYHVFRGANKQKHVFKQPKAPINGKPKVI-----GGKLLASGYNGIA  
 sm.pk0031.d12\_fis.PRO PAALVANCFTVLIGYHVFRGANKQKHVFKQPKAPINGKPKVI-----GGKLLASGYNGIA  
 8917585\_(Arabidopsis).PRO VPAIVVNCILVFLIGYHVFRGANKQKHVFKQPKAPINGKPKV-----GGKLLVSGYNGIA

p0097.cqrau67ra\_fis.PRO -----  
 src3c.pk009.c1\_fis.PRO RHONYLGDMLLALSFSLPQGVSSVPYFYPIYLLIILVLRERRDEARCSQKYREINAEYC  
 sm.pk0031.d12\_fis.PRO RHONYLGDMLLALSFSLPQGVSSVPYFYPIYLLIILVLRERRDEARCAEYREINAEYR  
 8917585\_(Arabidopsis).PRO RHONYLGDMLLALSFSLPQGVSSVPYFYPIYLLIILVLRERRDEVCAEYREINAEYL

p0097.cqrau67ra\_fis.PRO KLVFWRILPYVY  
 src3c.pk009.c1\_fis.PRO KLVFWRILPYVY  
 sm.pk0031.d12\_fis.PRO KLVFWRILPYVY  
 8917585\_(Arabidopsis).PRO KLVFWRILPYVY

(57) Abstract: This invention relates to an isolated nucleic acid fragment encoding a sterol delta-14 reductase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the sterol delta-14 reductase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the sterol delta-14 reductase in a transformed host cell.



IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *Without international search report and to be republished upon receipt of that report.*

TITLE

## GENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS

This application claims the benefit of U.S. Provisional Application No. 60/156820, filed September 30, 1999.

5

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding sterol delta-14 reductase in plants and seeds.

BACKGROUND OF THE INVENTION

10

Sterols are cyclic hydrocarbon molecules that help regulate the fluidity of cellular membranes. Sterols are essential components in all eukaryotic cells, and inhibitors that completely block sterol synthesis will block cell division and generally lead to cell death. In humans the predominant membrane sterol is cholesterol, which serves its structural role in membranes, and also serves as the precursor to hormones, bile salts, and modified

15 membrane components. In fungi, the predominant sterol is often ergosterol, which follows the same biosynthetic pathway as cholesterol but contains an additional methyl group and altered double-bond placements. In plants there are multiple sterols working in different combinations, with stigmasterol and sitosterol as the most common components. The plant sterols tend to have 29 carbons, versus the 28 carbons of ergosterol, and the 27 carbons of

20 cholesterol, but all are synthesized from the common precursors squalene and lanosterol.

The biosynthetic pathway leading to the final sterol products is long and complicated, requiring significant amounts of cellular energy to drive the multiple NADH (and/or NADPH) driven reduction steps. One enzyme in this pathway, sterol delta-14 reductase has been extensively studied in fungi because of its involvement in ergosterol

25 synthesis (Lai et al. (1994) *Gene* 140: 41-49; Parks et al. (1995) *Lipids* 30: 227-230). Mutants in sterol delta-14 reductase accumulate the aberrant sterol ignosterol, and can be supplemented with nutrients and growth conditions to survive (Palermo et al. (1997) *Curr Genet* 32: 93-99; Crowley et al. (1996) *J Bacteriol* 178: 2991-2993). The gene encoding this enzyme has been cloned and studied as a target for fungicidal agents (Marcireau et al.

30 (1992) *Curr Genet* 22: 267-272; Barrett-Bee and Dixon (1995) *Acta Biochim Pol* 42: 465-479).

Prior to the instant invention, no plant sterol delta-14 reductase genes have been isolated. Availability of such plant genes will enable one to alter sterol production and/or composition in plants, to identify compounds that may be used as novel herbicides and

35 fungicides, and to identify mutants of these genes that are resistant to these herbicides that will enable the production of herbicide-resistant crops.

### SUMMARY OF THE INVENTION

The present invention is directed to an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 126 amino acids having at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids having at least 82% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

In a second embodiment, it is preferred that the isolated polynucleotide of the claimed invention comprises a first nucleotide sequence which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.

In a third embodiment, this invention concerns an isolated polynucleotide comprising a nucleotide sequence of at least one of 300 (preferably at least one of 200, most preferably at least one of 125) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7 and the complement of such nucleotide sequences.

In a fourth embodiment, this invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to at least one suitable regulatory sequence.

In a fifth embodiment, the present invention concerns an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

In a sixth embodiment, the invention also relates to a process for producing an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention, the process comprising either transforming or transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

In a seventh embodiment, the invention concerns a plant sterol delta-14 reductase polypeptide of at least 126 amino acids comprising at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids comprising at least 82% identity based on the Clustal method of

alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8,.

In an eighth embodiment, the invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a plant sterol delta-14 reductase polypeptide or enzyme activity in a host cell, preferably a plant cell, the method comprising the steps of: (a) constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level of the plant sterol delta-14 reductase polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and (d) comparing the level of the plant sterol delta-14 reductase polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of the plant sterol delta-14 reductase polypeptide or enzyme activity in the host cell that does not contain the isolated polynucleotide.

In a ninth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of a plant sterol delta-14 reductase polypeptide, preferably a plant plant sterol delta-14 reductase polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of a plant sterol delta-14 reductase amino acid sequence.

In a tenth embodiment, this invention relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a plant sterol delta-14 reductase polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

In an eleventh embodiment, this invention concerns a composition, such as a hybridization mixture, comprising an isolated polynucleotide of the present invention.

In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette of the present invention; and (b) growing the transformed host cell, preferably a plant cell, such as a monocot or a dicot, under conditions

which allow expression of the plant sterol delta-14 reductase polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

In a thirteenth embodiment, this invention relates to a method of altering the level of expression of a sterol delta-14 reductase in a host cell comprising: (a) transforming a host cell with a chimeric gene of the present invention; and (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of the sterol delta-14 reductase in the transformed host cell.

A further embodiment of the instant invention is a method for evaluating at least one compound for its ability to inhibit the activity of a sterol delta-14 reductase, the method comprising the steps of: (a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding a sterol delta-14 reductase polypeptide, operably linked to suitable regulatory sequences; (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in altered production, and/or ratios, of phytosterols in the transformed host cell; (c) optionally purifying the sterol delta-14 reductase polypeptide expressed by the transformed host cell; (d) treating the sterol delta-14 reductase polypeptide with a compound to be tested; and (e) comparing the activity of the sterol delta-14 reductase polypeptide that has been treated with a test compound to the activity of an untreated sterol delta-14 reductase polypeptide, thereby selecting compounds with potential for inhibitory activity.

#### BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTINGS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

Figure 1 shows a comparison of the amino acid sequences encoded by a corn and two soybean sterol delta-14 reductase cDNAs (SEQ ID NOs:4, 6, and 8, respectively), and the *Arabidopsis thaliana* sequence (SEQ ID NO:10) that is the closest BLAST homolog.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.



TABLE 1  
Sterol Delta-14 Reductase

Protein	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Soybean sterol delta-14 reductase	src3c.pk009.c1	1	2
Corn sterol delta-14 reductase	p0097.cqrau67ra: fis	3	4
Soybean sterol delta-14 reductase	src3c.pk009.c1: fis	5	6
Soybean sterol delta-14 reductase	ssm.pk0031.d12: fis	7	8

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least one of 300 contiguous nucleotides, preferably 200 contiguous nucleotides, more preferably 125 nucleotides, again more preferably 60 contiguous nucleotides, once again more preferably at least one of 40 contiguous nucleotides, and most preferably one of at least 30 contiguous nucleotides derived from SEQ ID NOs:1, 3, 5, and 7, or the complement of such sequences.

The term "isolated" polynucleotide refers to a polynucleotide that is substantially free from other nucleic acid sequences, such as other chromosomal and extrachromosomal DNA and RNA, that normally accompany or interact with it as found in its naturally occurring environment. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides. The term also embraces recombinant polynucleotides and chemically synthesized polynucleotides.

The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than

the entire coding region of a gene, and by using nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of a plant sterol delta-14 reductase polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a virus or in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of a polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min,

then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C.

- 5 Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes

comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a “substantial portion” of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

“Codon degeneracy” refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic nucleic acid fragments” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. “Chemically synthesized”, as related to a nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding

sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature.

Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.

"Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign-gene" refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

"Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

"Translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is

present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

5       “3' non-coding sequences” refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

10       “RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA (mRNA)” refers to the RNA that is without introns and that can be translated into polypeptides by the cell. “cDNA” refers to DNA that is complementary to and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I. “Sense-RNA” refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. “Antisense RNA” refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. “Functional RNA” refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

25       The term “operably linked” refers to the association of two or more nucleic acid fragments on a single polynucleotide so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

30       The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. “Antisense inhibition” refers to the production of antisense RNA transcripts capable of

suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

A "protein" or "polypeptide" is a chain of amino acids arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. Each protein or polypeptide has a unique function.

"Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Null mutant" refers here to a host cell which either lacks the expression of a certain polypeptide or expresses a polypeptide which is inactive or does not have any detectable expected enzymatic function.

"Mature protein" or the term "mature" when used in describing a protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" or the term "precursor" when used in describing a protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050,



incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

"PCR" or "polymerase chain reaction" is well known by those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Patent Nos. 4,683,195 and 4,800,159).

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 126 amino acids having at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids having at least 82% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.

Nucleic acid fragments encoding at least a portion of several sterol delta-14 reductase have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST

algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but  
5 are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other plant sterol delta-14 reductase, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic  
10 acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, an entire sequence can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer  
15 DNA labeling, nick translation, end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of  
20 appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer  
25 is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to  
30 generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated  
35 by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 300 (preferably one of at least 200, most preferably

one of at least 125) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

5       The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a plant sterol delta-14 reductase polypeptide, preferably a substantial portion of a plant plant sterol delta-14 reductase polypeptide, comprising the steps of : synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous  
10       nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a plant sterol delta-14 reductase polypeptide.

15       Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then  
20       be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

      In another embodiment, this invention concerns viruses and host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide of the invention as described herein. Examples of host cells which can be used to practice  
25       the invention include, but are not limited to, yeast, bacteria, and plants.

      As was noted above, the nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of phytosterols in those cells.

30       Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription  
35       termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant isolated polynucleotide (or chimeric gene) may be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by directing the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of use may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation

available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of a specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

In another embodiment, the present invention concerns a polypeptide of at least 126 amino acids having at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids having at least 82% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded sterol delta-14 reductase. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

Additionally, the instant polypeptides can be used as a target to facilitate design and/or identification of inhibitors of those enzymes that may be useful as herbicides. This is

desirable because the polypeptides described herein catalyzes an important step in phytosterol biosynthesis. Accordingly, inhibition of the activity of one or more of the enzymes described herein could lead to inhibition of plant growth. Thus, the instant polypeptides could be appropriate for new herbicide discovery and design.

5 All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and used as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP)  
10 markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe  
15 Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

20 The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals  
25 may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

30 In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

35 A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism

of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

### 30 EXAMPLES

The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the

invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

### EXAMPLE 1

#### Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various corn and soybean tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Corn and Soybean

Library	Tissue	Clone
p0097	V9 7cm whorl section + ECB1, screened 1 B73+ECB1: 7-cm whorl section Growth conditions: field plots; these plants have been infested with ECB four times prior to harvest. Growth stage: unknown; V9 or V10	p0097.cqrau67ra: fis
src3c	Soybean 8 day old root infected with cyst nematode	src3c.pk009.c1
ssm	Soybean Shoot Meristem	ssm.pk0031.d12: fis

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

Full-insert sequence (FIS) data is generated utilizing a modified transposition protocol. Clones identified for FIS are recovered from archived glycerol stocks as single



colonies, and plasmid DNAs are isolated via alkaline lysis. Isolated DNA templates are reacted with vector primed M13 forward and reverse oligonucleotides in a PCR-based sequencing reaction and loaded onto automated sequencers. Confirmation of clone identification is performed by sequence alignment to the original EST sequence from which the FIS request is made.

Confirmed templates are transposed via the Primer Island transposition kit (PE Applied Biosystems, Foster City, CA) which is based upon the *Saccharomyces cerevisiae* Ty1 transposable element (Devine and Boeke (1994) *Nucleic Acids Res.* 22:3765-3772). The *in vitro* transposition system places unique binding sites randomly throughout a population of large DNA molecules. The transposed DNA is then used to transform DH10B electro-competent cells (Gibco BRL/Life Technologies, Rockville, MD) via electroporation. The transposable element contains an additional selectable marker (named DHFR; Fling and Richards (1983) *Nucleic Acids Res.* 11:5147-5158), allowing for dual selection on agar plates of only those subclones containing the integrated transposon. Multiple subclones are randomly selected from each transposition reaction, plasmid DNAs are prepared via alkaline lysis, and templates are sequenced (ABI Prism dye-terminator ReadyReaction mix) outward from the transposition event site, utilizing unique primers specific to the binding sites within the transposon.

Sequence data is collected (ABI Prism Collections) and assembled using Phred/Phrap (P. Green, University of Washington, Seattle). Phrep/Phrap is a public domain software program which re-reads the ABI sequence data, re-calls the bases, assigns quality values, and writes the base calls and quality values into editable output files. The Phrap sequence assembly program uses these quality values to increase the accuracy of the assembled sequence contigs. Assemblies are viewed by the Consed sequence editor (D. Gordon, University of Washington, Seattle).

## EXAMPLE 2

### Identification of cDNA Clones

cDNA clones encoding sterol delta-14 reductase were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all

publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

ESTs submitted for analysis are compared to the genbank database as described above. ESTs that contain sequences more 5- or 3-prime can be found by using the BLASTn algorithm (Altschul et al (1997) *Nucleic Acids Res.* 25:3389-3402.) against the Du Pont proprietary database comparing nucleotide sequences that share common or overlapping regions of sequence homology. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences can be assembled into a single contiguous nucleotide sequence, thus extending the original fragment in either the 5 or 3 prime direction. Once the most 5-prime EST is identified, its complete sequence can be determined by Full Insert Sequencing as described in Example 1. Homologous genes belonging to different species can be found by comparing the amino acid sequence of a known gene (from either a proprietary source or a public database) against an EST database using the tBLASTn algorithm. The tBLASTn algorithm searches an amino acid query against a nucleotide database that is translated in all 6 reading frames. This search allows for differences in nucleotide codon usage between different species, and for codon degeneracy.

### EXAMPLE 3

#### Characterization of cDNA Clones Encoding Sterol Delta-14 Reductase

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to soybean sterol delta-14 reductase from *Ascombolus immersus* (Genbank Accession No. 1805625). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs ("Contig\*"), or sequences encoding an entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

TABLE 3  
BLAST Results for Sequences Encoding Polypeptides Homologous  
to Soybean Sterol Delta-14 Reductase

Clone	Status	BLAST pLog Score [gi 1805625]
src3c.pk009.c1	EST	6.70

5       The sequence of the entire cDNA insert in the clones listed in Table 3 was  
determined. Further sequencing and searching of the DuPont proprietary database allowed  
the identification of other corn and soybean clones encoding sterol delta-14 reductase. The  
BLASTX search using the EST sequences from clones listed in Table 4 revealed similarity  
10    of the polypeptides encoded by the cDNAs to sterol delta-14 reductases from *Arabidopsis*  
*thaliana* (NCBI General Identifier Nos. gi 8917585 and gi 8980704). Shown in Table 4 are  
the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts  
comprising the indicated cDNA clones ("FIS"), sequences of contigs assembled from two or  
more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs  
("Contig\*"), or sequences encoding the entire protein derived from an FIS, a contig, or an  
15    FIS and PCR ("CGS"):

TABLE 4  
BLAST Results for Sequences Encoding Polypeptides Homologous  
to *Arabidopsis* Sterol Delta-14 Reductases

Clone	Status	BLAST pLog Score gi 8917585
p0097.cqrau67ra: fis	FIS	62.70
src3c.pk009.c1: fis	FIS	>180.00
ssm.pk0031.d12: fis	FIS	174.00

20

Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID  
NOs:4, 6, and 8, and the *Arabidopsis thaliana* sequence (SEQ ID NO:10). The data in  
Table 5 represents a calculation of the percent identity of the amino acid sequences set forth  
25    in SEQ ID NOs:2, 4, 6, and 8, and the *Ascobolus immersus* and the *Arabidopsis thaliana*  
sequences (SEQ ID NOs:9 and 10). The nucleotide and polypeptide sequences contained in  
SEQ ID NOs:1 and 2, respectively, were part of the provisional filing of this application  
(U.S. Provisional Application No. 60/156820, filed September 30, 1999). The closest art at  
the time of the provisional filing was the *Ascobolus immersus* enzyme. The *Arabidopsis*  
30    Genbank submission is dated July 5, 2000. The percent identity of SEQ ID NO:2 to the

*Arabidopsis thaliana* sequence (SEQ ID NO:10, Jang et al. (2000) *Genes Dev.* 14:1485-1497) is 64.3%.

**TABLE 5**

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to Sterol Delta-14 Reductases

SEQ ID NO.	Percent Identity to	
	gi 1805625	gi 8917585
2	21.4%	
4		76.4%
6		81.1%
8		78.6%

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a sterol delta-14 reductase. These sequences represent the first plant (SEQ ID NO:2) and first corn and soybean sequences encoding sterol delta-14 reductase known to Applicant.

#### **EXAMPLE 4**

##### **Expression of Chimeric Genes in Monocot Cells**

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from

pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* 5 XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment 10 encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed 15 with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can 20 be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers 25 resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be 30 used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. 35 After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles

resuspended in a final volume of 30  $\mu$ L of ethanol. An aliquot (5  $\mu$ L) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing gluphosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 5

##### Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment

when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

5 Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic  
10 embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of  
15 tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

20 A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression  
25 cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µL spermidine (0.1 M), and 50 µL CaCl<sub>2</sub> (2.5 M). The particle  
30 preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

35 Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally

bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

- 5 Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into  
10 individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

#### EXAMPLE 6

##### Expression of Chimeric Genes in Microbial Cells

- The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in  
20 pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region,  
25 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

- Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% low melting agarose gel. Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel  
30 by digestion with GELase™ (Epicentre Technologies, Madison, WI) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs (NEB), Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The  
35 vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5



electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

5 For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 10 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant 15 determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

#### EXAMPLE 7

##### Evaluating Compounds for Their Ability to Inhibit the Activity 20 of Sterol Delta-14 Reductase

The polypeptides described herein may be produced using any number of methods known to those skilled in the art. Such methods include, but are not limited to, expression in bacteria as described in Example 6, or expression in eukaryotic cell culture, *in planta*, and using viral expression systems in suitably infected organisms or cell lines. The instant 25 polypeptides may be expressed either as mature forms of the proteins as observed *in vivo* or as fusion proteins by covalent attachment to a variety of enzymes, proteins or affinity tags. Common fusion protein partners include glutathione S-transferase ("GST"), thioredoxin ("Trx"), maltose binding protein, and C- and/or N-terminal hexahistidine polypeptide ("His<sub>6</sub>"). The fusion proteins may be engineered with a protease recognition site at the 30 fusion point so that fusion partners can be separated by protease digestion to yield intact mature enzyme. Examples of such proteases include thrombin, enterokinase and factor Xa. However, any protease can be used which specifically cleaves the peptide connecting the fusion protein and the enzyme.

Purification of the instant polypeptides, if desired, may utilize any number of 35 separation technologies familiar to those skilled in the art of protein purification. Examples of such methods include, but are not limited to, homogenization, filtration, centrifugation, heat denaturation, ammonium sulfate precipitation, desalting, pH precipitation, ion exchange

chromatography, hydrophobic interaction chromatography and affinity chromatography, wherein the affinity ligand represents a substrate, substrate analog or inhibitor. When the instant polypeptides are expressed as fusion proteins, the purification protocol may include the use of an affinity resin which is specific for the fusion protein tag attached to the expressed enzyme or an affinity resin containing ligands which are specific for the enzyme. For example, the instant polypeptides may be expressed as a fusion protein coupled to the C-terminus of thioredoxin. In addition, a (His)<sub>6</sub> peptide may be engineered into the N-terminus of the fused thioredoxin moiety to afford additional opportunities for affinity purification. Other suitable affinity resins could be synthesized by linking the appropriate ligands to any suitable resin such as Sepharose-4B. In an alternate embodiment, a thioredoxin fusion protein may be eluted using dithiothreitol; however, elution may be accomplished using other reagents which interact to displace the thioredoxin from the resin. These reagents include  $\beta$ -mercaptoethanol or other reduced thiol. The eluted fusion protein may be subjected to further purification by traditional means as stated above, if desired. Proteolytic cleavage of the thioredoxin fusion protein and the enzyme may be accomplished after the fusion protein is purified or while the protein is still bound to the ThioBond™ affinity resin or other resin.

Crude, partially purified or purified enzyme, either alone or as a fusion protein, may be utilized in assays for the evaluation of compounds for their ability to inhibit enzymatic activation of the instant polypeptides disclosed herein. Assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. For example, assays for sterol delta-14 reductase are presented by Steel (1991) *J Chromatogr* 31:435-43.

CLAIMS

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
  - (a) a first nucleotide sequence encoding a polypeptide of at least  
5 126 amino acids having a sequence identity of at least 50% based on  
the Clustal method of alignment when compared to a polypeptide  
consisting of SEQ ID NO:2, and
  - (b) a second nucleotide sequence encoding a polypeptide of at least  
10 369 amino acids having a sequence identity of at least 82% based on  
the Clustal method of alignment when compared to a polypeptide  
selected from the group consisting of SEQ ID NOs:4, 6, and 8.
2. A polynucleotide sequence of Claim 1, wherein sequence identity is at least 85%.
3. A polynucleotide sequence of Claim 1, wherein sequence identity is at least 90%.
4. A polynucleotide sequence of Claim 1, wherein sequence identity is at least 95%.
- 15 5. The polynucleotide of Claim 1 wherein the polynucleotide encodes a polypeptide  
selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.
6. An isolated polynucleotide comprising a nucleotide sequence of at least  
125 contiguous nucleotides from a nucleotide sequence selected from the group consisting of  
SEQ ID NOs:1, 3, 5, and 7.
- 20 7. The polynucleotide of Claim 6, wherein the polynucleotide comprises a  
nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, and 7.
8. The polynucleotide of Claim 1, wherein the polypeptide is a
9. An isolated complement of the polynucleotide of Claim 1, wherein (a) the  
complement and the polynucleotide consist of the same number of nucleotides, and (b) the  
25 nucleotide sequences of the complement and the polynucleotide have 100%  
complementarity.
10. An isolated nucleic acid molecule that hybridizes with the isolated  
polynucleotide of Claim 1 under a hybridization condition of 0.1X SSC, 0.1% SDS, and  
65°C.
- 30 11. A cell comprising the polynucleotide of Claim 1.
12. The cell of Claim 11, wherein the cell is selected from the group consisting of a  
yeast cell, a bacterial cell and a plant cell.
13. A transgenic plant comprising the polynucleotide of Claim 1.
14. A method for transforming a cell comprising introducing into a cell the  
35 polynucleotide of Claim 1.

15. A method for producing a transgenic plant comprising (a) transforming a plant cell with the polynucleotide of Claim 1, and (b) regenerating a plant from the transformed plant cell.

5 16. A method for producing a polynucleotide fragment comprising (a) selecting a nucleotide sequence comprised by the polynucleotide of Claim 1, and (b) synthesizing a polynucleotide fragment containing the nucleotide sequence.

17. The method of Claim 16, wherein the fragment is produced *in vivo*.

10 18. An isolated polypeptide selected from the group consisting of (a) a first polypeptide of at least 126 amino acids having a sequence identity of at least 50% based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, and (b) a second polypeptide of at least 369 amino acids having a sequence identity of at least 82% based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8.

15 19. The polypeptide of Claim 18, wherein the sequence identity is at least 85%.

20. The polypeptide of Claim 19, wherein the sequence identity is at least 90%.

21. The polypeptide of Claim 19, wherein the sequence identity is at least 95%.

22. The polypeptide of Claim 19 wherein the polypeptide has a sequence selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.

20 23. The polypeptide of Claim 18, wherein the polypeptide is a sterol delta-14 reductase.

24. A chimeric gene comprising the polynucleotide of Claim 1 operably linked to at least one suitable regulatory sequence.

25. A method for altering the level of sterol delta-14 reductase expression in a host cell, the method comprising:

- 25 (a) Transforming a host cell with the chimeric gene of Claim 24; and  
(b) Growing the transformed cell in step (a) under conditions suitable for the expression of the chimeric gene.

26. The method of Claim 25 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7.

FIGURE 1 Comparison of the Corn, Soybean (2), and Arabidopsis Sterol Delta-14 Reductases

```

p0097.cqrau67ra_fis.PRO
src3c.pk009.cl_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----
M-----MESHVDLGFLLOALTPSWNSVPLLVG-----
M-----MESHVDLGFLLOALTPSWNSVPLLVG-----
M-----MESHVDLGFLLOALTPSWNSVPLLVG-----
M-----DLGVLLPSL-----QSVYVLVF-----

p0097.cqrau67ra_fis.PRO
src3c.pk009.cl_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----
-----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA-----PRVR-----KNKVELSLLSGLANLC-----
-----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA-----
-----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA-----
-----YFVYLAVAGEILPGKLVIRGVLLSDGSQLRYRCNGLLALILLVAILGICA-----

p0097.cqrau67ra_fis.PRO
src3c.pk009.cl_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----
KMGEVSPT-----AISDRGLELLSTTFASFVLVTILHFSGCKSQSKGSS--LKPH-LSG
KMGEVSPT-----AISDRGLELLSTTFASFVLVTILHFSGCKSQSKGSS--LKPH-LSG
KLGIVSPL-----VVADRGLELLSATFICVLVTILALYVTGRSSNKGSS--LKPH-VSG

p0097.cqrau67ra_fis.PRO
src3c.pk009.cl_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----
NLIHDWWFGIQLNPQFMG-IDLKFFF-VRAGMGMWLLINLSILMKSIQ-DGTLQSQMILY
NLIHDWWFGIQLNPQFMG-IDLK-----AGMGMWLLINLSILMKSIQ-DGTLQSQMILY
NLVHDWWFGIQLNPQFMS-IDLKFFF-VRAGMGMWLLINLSILAKSVQ-DGSLQSQMILY

p0097.cqrau67ra_fis.PRO
src3c.pk009.cl_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----
QLFCALYILDYFVHEEYNTSTWDIIAERLGFMLVFGDLVWIPFSSIQGWLLMNSVELT
QLFCALYILDYFVHEEYNTSTWDIIAERLGFMLVFGDLVWIPFSSIQGWLLMNSVELT
QIFCALYILDYFVHEEYNTSTWDIIAERLGFMLVFGDLLWIPFTFSIQGWLLHNKVELT

p0097.cqrau67ra_fis.PRO
src3c.pk009.cl_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----
-----IFLIGYLVFRGANKQKHVEKKDPKAPIWGKPPKV-----GGKLLASGYWGIA
PAAIVANCFVFLIGYMWFRGANKQKHVEKKDPKAPIWGKPPKVI-----GGKLLASGYWGIA
PAAIVANCFVFLIGYMWFRGANKQKHVEKKDPKAPIWGKPPKVI-----GGKLLASGYWGIA
VPAIVVNCLVFLIGYMWFRGANKQKHIFKKNPKTPIWGKPPVV-----GGKLLVSGYWGIA

```

JC13 Rec'd PCT/PTO 19 FEB 2002

FIGURE 1 (page 2 of 2)

p0097.cqrau67ra_fis.PRO	RHCNYLGDLLLALSFSLPCGVSSVVPYFYFTYLLILLVLRERRDEARCSQKYREIWAEC
src3c.pk009.cl_fis.PRO	RHCNYLGDLMLALSFSLPCGISSPIPYFYPIYLLILLIWRERRDEARCAEKYREIWAEC
ssm.pk0031.d12_fis.PRO	RHCNYLGDLMLALSFSLPCGISSPIPYFYPIYLLILLIWRERTDEARCAEKYREIWAEC
8917585_(Arabidopsis).PRO	RHCNYLGDLMLALSFSLPCGISSVVPYFYPIYLLILLIWRERRDEVRCAEKYKEIWAEC
p0097.cqrau67ra_fis.PRO	KLVPWRILPYVY
src3c.pk009.cl_fis.PRO	KLVPWRILPYVY
ssm.pk0031.d12_fis.PRO	KLVPWRILPYVY
8917585_(Arabidopsis).PRO	RLVPWRILPYVY





SEQUENCE LISTING

&lt;110&gt; E.I. du Pont de Nemours and Company

&lt;120&gt; Genes Encoding Sterol Delta-14 Reductase in Plants

&lt;130&gt; BB1395 PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/156,820

&lt;151&gt; 1999-09-30

&lt;160&gt; 10

&lt;170&gt; Microsoft Office 95

&lt;210&gt; 1

&lt;211&gt; 427

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (360)

&lt;400&gt; 1

```

gtgatgatgg agtcacacgt ggatctaggt tttctccttc aagctctcac tccatcttgg 60
aactccgttc ctttgcttgt ggggttcttc acttacttgg ccgttgctgg atccattctc 120
cctggaaaac ttgttcttgg cgttgcacta ctcgatggaa ctcgctctaca ctattgctgc 180
aatggtctgc tctcgcttct tctgttggtt gcacttctcg ggatcggtgc caagatgggt 240
tttgtgtctc ccactgccat atcaaacaga ggacttgagc tgctgtccac aacttttgcc 300
ttcagttttc ttgtaaccct gatattgcat ttttccgggt gcaagtcaca aagtaaaggc 360
tcatcactaa agcctcatct cagtgggaac ctgatacacg attggtgggt tgggaatata 420
actaaaa

```

&lt;210&gt; 2

&lt;211&gt; 126

&lt;212&gt; PRT

&lt;213&gt; Glycine max

&lt;400&gt; 2

```

Leu Gln Ala Leu Thr Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly
 1              5              10              15

Phe Phe Thr Tyr Leu Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu
          20              25              30

Val Pro Gly Val Ala Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys
          35              40              45

Asn Gly Leu Leu Ser Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly
          50              55              60

Ala Lys Met Gly Phe Val Ser Pro Thr Ala Ile Ser Asn Arg Gly Leu
          65              70              75              80

```



Pro His Leu Ser Gly Asn Leu Ile His Asp Trp Trp Phe Gly  
115 120 125

```
<210> 3
<211> 1631
<212> DNA
<213> Glycine max
```

<400>	3						
ccgcgttgga	atttgcccat	ctaaaacctc	aatcttttac	tgaaaagtct	caactttgaa		60
ctcactcgaa	gtgatgatgg	agtcacacgt	ggatctagggt	tttctccttc	aagctctcac		120
tccatcttgg	aactccgttc	ctttgcttgt	ggggttcttc	acttacttgg	ccgttgctgg		180
atccattctc	cctggaaaac	ttgttctctg	cgttgcacta	ctcgatggaa	ctcgtctaca		240
ctattgtctg	aatgggtctg	tctcgcttct	tctgtgggt	gcacttctcg	ggatcgggtg		300
caagatgggt	tttgtgtctc	ccactgccat	atcagacaga	ggacttgagc	tgctgtccac		360
aacttttgcc	ttcagttttc	ttgtaaccct	gatattgcat	ttttccggtt	gcaagtcaca		420
aagtaaagggt	tcataactaa	agcctcatct	cagtggaaac	ctgatacacg	attgggtggt		480
tggtatacaa	ctaaatccac	agttcatggg	tatcgacctc	aaatttttct	ttgttagagc		540
tggaatgatg	ggatggctac	ttatcaattt	atctattctt	atgaagagca	ttcaagatgg		600
tactttgagc	cagtcaatga	ttctctacca	gctattctgt	gcatacata	tcttggacta		660
ttttgtacat	gaagagtaca	tgacatccac	ctggacata	attgcagaga	gactgggctt		720
catgttggtc	ttggagatt	tagtgtggat	tcctttctct	ttcagcatac	agggatgggtg		780
gctcttgatg	aacagtggtg	agttaacacc	agctgccatt	gtagctaatt	gctttgtgtt		840
cctgattgga	tacatggtat	ttcgaggagc	aaacaagcaa	aagcatgtgt	tcaaaaagaa		900
tccaaaggct	cctatctggg	gtaagcctcc	aaaagtcatt	ggtggaaagc	tacttgcttc		960
tggttatttg	ggtattgcta	gacactgtaa	ttacctagggt	gatttgatgc	ttgctctctc		1020
ctttagctta	ccatgtggga	taagttcacc	aattccatac	ttctatccaa	tttatcttct		1080
tattctgtta	atctggagag	agagaaggga	tgaagctcgt	tgcgccgaga	agtatagaga		1140
gatatgggcc	gagtatcgta	aacttgttcc	atggagaata	ttgccttacg	tttattagga		1200
tgaaaaaaaa	aagggttcca	ccatgaattc	ttcatcttgc	cgatgttatt	aagcacttcg		1260
atgtaaattg	gttcttgttc	ttgtgggttc	aatcttggat	cttttcttat	tgagccatgt		1320
agctgcagga	gagtgtttcg	agggatttat	cttaccatct	atatttgtgt	atcattatgc		1380
tgacgcctgc	aggccttcat	ttttcaatgg	ccaactcttt	ttgacttggt	ctatttgttt		1440
ttagatgaga	atttcatggt	caaagctcct	aggcttaaaa	aaacagtgtc	atgttctatg		1500
ggaagtgcag	gaagcaattc	ggggactgca	ggaagcaatt	gcctttacat	tgatatgtc		1560
aatggtactt	taggcccttt	aatgttcttg	cttttcattt	gtgagttatt	attggcccca		1620
tttcatttgc	a						1631

```
<210> 4
<211> 374
<212> PRT
<213> Glycine max
```

```

<400> 4
Met Met Glu Ser His Val Asp Leu Gly Phe Leu Leu Gln Ala Leu Thr
  1             5             10             15

Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly Phe Phe Thr Tyr Leu
      20             25             30

Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu Val Pro Gly Val Ala
      35             40             45

```



Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys Asn Gly Leu Leu Ser  
 50 55 60  
 Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly Ala Lys Met Gly Phe  
 65 70 75 80  
 Val Ser Pro Thr Ala Ile Ser Asp Arg Gly Leu Glu Leu Leu Ser Thr  
 85 90 95  
 Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile Leu His Phe Ser Gly  
 100 105 110  
 Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys Pro His Leu Ser Gly  
 115 120 125  
 Asn Leu Ile His Asp Trp Trp Phe Gly Ile Gln Leu Asn Pro Gln Phe  
 130 135 140  
 Met Gly Ile Asp Leu Lys Phe Phe Phe Val Arg Ala Gly Met Met Gly  
 145 150 155 160  
 Trp Leu Leu Ile Asn Leu Ser Ile Leu Met Lys Ser Ile Gln Asp Gly  
 165 170 175  
 Thr Leu Ser Gln Ser Met Ile Leu Tyr Gln Leu Phe Cys Ala Leu Tyr  
 180 185 190  
 Ile Leu Asp Tyr Phe Val His Glu Glu Tyr Met Thr Ser Thr Trp Asp  
 195 200 205  
 Ile Ile Ala Glu Arg Leu Gly Phe Met Leu Val Phe Gly Asp Leu Val  
 210 215 220  
 Trp Ile Pro Phe Ser Phe Ser Ile Gln Gly Trp Trp Leu Leu Met Asn  
 225 230 235 240  
 Ser Val Glu Leu Thr Pro Ala Ala Ile Val Ala Asn Cys Phe Val Phe  
 245 250 255  
 Leu Ile Gly Tyr Met Val Phe Arg Gly Ala Asn Lys Gln Lys His Val  
 260 265 270  
 Phe Lys Lys Asn Pro Lys Ala Pro Ile Trp Gly Lys Pro Pro Lys Val  
 275 280 285  
 Ile Gly Gly Lys Leu Leu Ala Ser Gly Tyr Trp Gly Ile Ala Arg His  
 290 295 300  
 Cys Asn Tyr Leu Gly Asp Leu Met Leu Ala Leu Ser Phe Ser Leu Pro  
 305 310 315 320  
 Cys Gly Ile Ser Ser Pro Ile Pro Tyr Phe Tyr Pro Ile Tyr Leu Leu  
 325 330 335  
 Ile Leu Leu Ile Trp Arg Glu Arg Arg Asp Glu Ala Arg Cys Ala Glu  
 340 345 350  
 Lys Tyr Arg Glu Ile Trp Ala Glu Tyr Arg Lys Leu Val Pro Trp Arg  
 355 360 365



Ile Leu Pro Tyr Val Tyr  
370

<210> 5  
<211> 667  
<212> DNA  
<213> Zea mays

<400> 5  
ccacgcgtcc ggaagaacaa agtagagctg tcccttttgt ctggtctagc taacttatgc 60  
atctttctta ttggctacct agtggtccga ggagctaaca agcaaaaaca tgtgttcaag 120  
aaggacccca aagctcctat atggggaaaa cctcccaaag ttgtcggggg aaagctacta 180  
gcatctggtt actggggcat cgcaaggcac tgcaattatc tcggagacct gctgctagca 240  
ctttcgttca gcttgccctg tggagtgagt tccgtggtcc catacttcta cccacgtac 300  
ctgctcattc tactggtctt gagggaaagg cgcgatgagg cgagggtgctc gcagaagtac 360  
agggagatct gggcagagta ctgcaagctc gtgccgtgga ggatcctgcc ttatgtgtac 420  
tgaagagacg gtagaaacca aggcagctca tggccctggg ccagctgtaa acctatattt 480  
gtttgccctt aaccagttgg tgaatgttga tgtagcactc ggtaaaactgt gaccgtgcaa 540  
acttttggtt ttgttggtcc atacatgttt ggaatcgtga atcagaccgc ctcacttggg 600  
ggcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 660  
aaaaaag 667

<210> 6  
<211> 140  
<212> PRT  
<213> Zea mays

<400> 6  
Pro Arg Val Arg Lys Asn Lys Val Glu Leu Ser Leu Leu Ser Gly Leu  
1 5 10 15  
Ala Asn Leu Cys Ile Phe Leu Ile Gly Tyr Leu Val Phe Arg Gly Ala  
20 25 30  
Asn Lys Gln Lys His Val Phe Lys Lys Asp Pro Lys Ala Pro Ile Trp  
35 40 45  
Gly Lys Pro Pro Lys Val Val Gly Gly Lys Leu Leu Ala Ser Gly Tyr  
50 55 60  
Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly Asp Leu Leu Leu Ala  
65 70 75 80  
Leu Ser Phe Ser Leu Pro Cys Gly Val Ser Ser Val Val Pro Tyr Phe  
85 90 95  
Tyr Pro Thr Tyr Leu Leu Ile Leu Leu Val Leu Arg Glu Arg Arg Asp  
100 105 110  
Glu Ala Arg Cys Ser Gln Lys Tyr Arg Glu Ile Trp Ala Glu Tyr Cys  
115 120 125  
Lys Leu Val Pro Trp Arg Ile Leu Pro Tyr Val Tyr  
130 135 140





<210> 7  
 <211> 1364  
 <212> DNA  
 <213> Glycine max

<400> 7  
 ttccggcagca gtaaaacctc aatctttttac tgaaaagtct caactttgaa ctcactcgaa 60  
 gtgatgatgg agtcacacgt ggatctaggt tttctccttc aagctctcac tccatcttgg 120  
 aactccgttc ctttgcttgt ggggttcttc acttacttgg ccgttgctgg atccattctc 180  
 cctggaaaac ttgttcctgg cgttgcaacta ctcgatggaa ctctgtctaca ctattgctgc 240  
 aatgggtctgc tctcgcttct tctgttggtt gcactttctcg ggatcgggtgc caagatgggt 300  
 tttgtgtctc ccactgccat atcagacaga ggacttgagc tgctgtccac aacttttgcc 360  
 ttcagttttc ttgtaaccct gatattgcat ttttccggtt gcaagtcaca aagtaaagggt 420  
 tcatcactaa agcctcatct cagtggaaac ctgatacacg attggtgggt tggtatacaa 480  
 ctaaattccac agttcatggg tatcgacctc aaagctggaa tgatgggatg gctacttatt 540  
 aatttatcta ttcttatgaa gagcattcaa gatggtactt tgagccagtc aatgattctc 600  
 taccagctat tctgtgcact atacatcctg gactattttg tacatgaaga gtacatgaca 660  
 tccacctggg acataattgc agagagactg ggcttcatgt tggctcttgg agatttagtg 720  
 tggattcctt tctctttcag catacagga tggtggctct tgatgaacag tgtggagtta 780  
 acaccagctg ccattgtagc taattgcttt gtgttcctga ttggatacat ggtatttcga 840  
 ggagcaaaac agcaaaaagca tgtgttcaaa aagaatccaa aggctcctat ctggggtaag 900  
 cctccaaaag tcattggtgg aaagctactt gcttctgggt attgggggtat tgctagacac 960  
 tgtaattacc taggggattt gatgcttgct ctctccttta gcttaccatg tgggataagt 1020  
 tcaccaattc catacttcta tccaatttat cttcttattc tgtaaatctg gagagagaga 1080  
 acggatgaag ctctgtgcgc cgagaagat agagagatat gggccagata tcgtaaaactt 1140  
 gttccatgga gaattattgcc ttacgtttat taggatgaaa aaaaaaaggg cttcaccatg 1200  
 aattcttcat cttgccgatg ttattaagca ctctgatgta aattggttct tgttcttctg 1260  
 gtttcaatct tggatctttt cttattgagc catgtagctg caggagagtg tttcgagggg 1320  
 tttatcttac catctatatt tgtgtaaaaa aaaaaaaaaa aaaa 1364

<210> 8  
 <211> 369  
 <212> PRT  
 <213> Glycine max

<400> 8  
 Met Met Glu Ser His Val Asp Leu Gly Phe Leu Leu Gln Ala Leu Thr  
 1 5 10 15  
 Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly Phe Phe Thr Tyr Leu  
 20 25 30  
 Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu Val Pro Gly Val Ala  
 35 40 45  
 Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys Asn Gly Leu Leu Ser  
 50 55 60  
 Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly Ala Lys Met Gly Phe  
 65 70 75 80  
 Val Ser Pro Thr Ala Ile Ser Asp Arg Gly Leu Glu Leu Leu Ser Thr  
 85 90 95  
 Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile Leu His Phe Ser Gly  
 100 105 110  
 Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys Pro His Leu Ser Gly  
 115 120 125



Asn Leu Ile His Asp Trp Trp Phe Gly Ile Gln Leu Asn Pro Gln Phe  
 130 135 140  
 Met Gly Ile Asp Leu Lys Ala Gly Met Met Gly Trp Leu Leu Ile Asn  
 145 150 155 160  
 Leu Ser Ile Leu Met Lys Ser Ile Gln Asp Gly Thr Leu Ser Gln Ser  
 165 170 175  
 Met Ile Leu Tyr Gln Leu Phe Cys Ala Leu Tyr Ile Leu Asp Tyr Phe  
 180 185 190  
 Val His Glu Glu Tyr Met Thr Ser Thr Trp Asp Ile Ile Ala Glu Arg  
 195 200 205  
 Leu Gly Phe Met Leu Val Phe Gly Asp Leu Val Trp Ile Pro Phe Ser  
 210 215 220  
 Phe Ser Ile Gln Gly Trp Trp Leu Leu Met Asn Ser Val Glu Leu Thr  
 225 230 235 240  
 Pro Ala Ala Ile Val Ala Asn Cys Phe Val Phe Leu Ile Gly Tyr Met  
 245 250 255  
 Val Phe Arg Gly Ala Asn Lys Gln Lys His Val Phe Lys Lys Asn Pro  
 260 265 270  
 Lys Ala Pro Ile Trp Gly Lys Pro Pro Lys Val Ile Gly Gly Lys Leu  
 275 280 285  
 Leu Ala Ser Gly Tyr Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly  
 290 295 300  
 Asp Leu Met Leu Ala Leu Ser Phe Ser Leu Pro Cys Gly Ile Ser Ser  
 305 310 315 320  
 Pro Ile Pro Tyr Phe Tyr Pro Ile Tyr Leu Leu Ile Leu Leu Ile Trp  
 325 330 335  
 Arg Glu Arg Thr Asp Glu Ala Arg Cys Ala Glu Lys Tyr Arg Glu Ile  
 340 345 350  
 Trp Ala Glu Tyr Arg Lys Leu Val Pro Trp Arg Ile Leu Pro Tyr Val  
 355 360 365  
 Tyr  
 369

&lt;210&gt; 9

&lt;211&gt; 430

&lt;212&gt; PRT

&lt;213&gt; Ascobolus immersus

&lt;400&gt; 9

Met Gly Gly Lys Asp Tyr Glu Phe Gly Gly Pro Ile Gly Thr Gly Val  
 1 5 10 15

Leu Met Leu Ile Leu Pro Pro Ile Ser His Tyr Leu His Phe Leu Ile  
 20 25 30



Thr Pro Arg Gly Ala Pro Pro Pro Glu Phe Trp Ser Ala Pro Leu Glu  
 35 40 45  
 Thr Leu Lys Ser Val Thr Pro Thr Phe Ser Ser Leu Phe Ser Leu His  
 50 55 60  
 Ala Thr Leu Ala Val Ala Ala Tyr Tyr Leu Leu Val Ala Leu Met  
 65 70 75 80  
 Tyr Val Leu Pro Ala Glu Ile Ala Glu Gly Val Val Leu Lys Asp Gly  
 85 90 95  
 Ser Arg Leu Lys Tyr Arg Cys Asn Ala Phe Thr Thr Phe Leu Val Phe  
 100 105 110  
 Phe Thr Phe Leu Gly Thr Met Thr Val Leu Glu Gly Pro Thr Trp Trp  
 115 120 125  
 Phe Trp Ser Tyr Leu Thr Asp Asn Phe Ala Gln Leu Gln Ser Ala Ser  
 130 135 140  
 Ile Val Phe Ser Tyr Ala Met Ser Leu Trp Val Tyr Ile Arg Ser Tyr  
 145 150 155 160  
 Arg Pro Met Pro Lys Gly Lys Glu Val Ile Leu Ser Pro Val Gly Phe  
 165 170 175  
 Lys Gly Asn His Ile His Asp Phe Trp Met Gly Arg Glu Leu Asn Pro  
 180 185 190  
 Arg Ile Gly Glu Trp Leu Asp Ile Lys Gln Leu His Glu Leu Arg Pro  
 195 200 205  
 Gly Leu Met Gly Trp Ile Leu Phe Asn Leu Ala Trp Thr Val Lys Gln  
 210 215 220  
 Tyr Asn Thr His Gly Phe Val Ser Asp Ser Ile Val Leu Val Asn Leu  
 225 230 235 240  
 Phe Glu Thr Trp Tyr Val Val Asp Ala Leu Trp Asn Glu Ser Lys Val  
 245 250 255  
 Leu Thr Thr Met Asp Ile Thr Thr Asp Gly Leu Gly Val Met Leu Leu  
 260 265 270  
 Phe Gly Asn Ala Val Trp Val Pro Phe Met Tyr Cys Leu Gln Ala Arg  
 275 280 285  
 Tyr Leu Ala Ser Phe Pro Val His Leu Gly Leu Leu Gly Ile Ala Gly  
 290 295 300  
 Val Leu Ala Val Gln Phe Thr Gly Tyr Ala Ile Phe Arg Gly Ala Asn  
 305 310 315 320  
 Asn Gln Lys Asn Ala Phe Arg Thr Asn Pro Ala Asp Pro Ala Val Ser  
 325 330 335  
 His Leu Lys Phe Met Thr Thr Lys Ser Gly Ser Lys Leu Leu Ile Ser  
 340 345 350



Gly Trp Trp Gly Val Ala Arg His Val Asn Tyr Phe Gly Asp Trp Ile  
 355 360 365

Met Ala Trp Ser Tyr Cys Leu Thr Thr Gly Phe Asn Thr Pro Leu Thr  
 370 375 380

Tyr Phe Tyr Val Ile Tyr Phe Gly Ile Leu Leu Leu His Arg Asp Arg  
 385 390 395 400

Arg Asp Glu Ala Lys Cys Arg Glu Lys Tyr Gly Lys Asp Trp Asp Arg  
 405 410 415

Tyr Cys Lys Val Val Lys Trp Arg Ile Ile Pro Gly Ile Tyr  
 420 425 430

<210> 10

<211> 365

<212> PRT

<213> Arabidopsis thaliana

<400> 10

Met Asp Leu Gly Val Leu Leu Pro Ser Leu Gln Ser Val Tyr Val Leu  
 1 5 10 15

Val Phe Tyr Phe Val Tyr Leu Ala Val Ala Gly Glu Ile Leu Pro Gly  
 20 25 30

Lys Val Ile Arg Gly Val Leu Leu Ser Asp Gly Ser Gln Leu Arg Tyr  
 35 40 45

Arg Cys Asn Gly Leu Leu Ala Leu Ile Leu Leu Val Ala Ile Leu Gly  
 50 55 60

Ile Cys Ala Lys Leu Gly Ile Val Ser Pro Leu Val Val Ala Asp Arg  
 65 70 75 80

Gly Leu Glu Leu Leu Ser Ala Thr Phe Ile Phe Cys Val Leu Val Thr  
 85 90 95

Leu Ala Leu Tyr Val Thr Gly Arg Ser Ser Ser Asn Lys Gly Ser Ser  
 100 105 110

Leu Lys Pro His Val Ser Gly Asn Leu Val His Asp Trp Trp Phe Gly  
 115 120 125

Ile Gln Leu Asn Pro Gln Phe Met Ser Ile Asp Leu Lys Phe Phe Phe  
 130 135 140

Val Arg Ala Gly Met Met Gly Trp Leu Leu Ile Asn Leu Ser Ile Leu  
 145 150 155 160

Ala Lys Ser Val Gln Asp Gly Ser Leu Ser Gln Ser Met Ile Leu Tyr  
 165 170 175

Gln Ile Phe Cys Ala Leu Tyr Ile Leu Asp Tyr Phe Val His Glu Glu  
 180 185 190





Tyr Met Thr Ser Thr Trp Asp Ile Ile Ala Glu Arg Leu Gly Phe Met  
 195 200 205  
 Leu Val Phe Gly Asp Leu Leu Trp Ile Pro Phe Thr Phe Ser Ile Gln  
 210 215 220  
 Gly Trp Trp Leu Leu His Asn Lys Val Glu Leu Thr Val Pro Ala Ile  
 225 230 235 240  
 Val Val Asn Cys Leu Val Phe Leu Ile Gly Tyr Met Val Phe Arg Gly  
 245 250 255  
 Ala Asn Lys Gln Lys His Ile Phe Lys Lys Asn Pro Lys Thr Pro Ile  
 260 265 270  
 Trp Gly Lys Pro Pro Val Val Val Gly Gly Lys Leu Leu Val Ser Gly  
 275 280 285  
 Tyr Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly Asp Leu Met Leu  
 290 295 300  
 Ala Leu Ser Phe Ser Leu Pro Cys Gly Ile Ser Ser Pro Val Pro Tyr  
 305 310 315 320  
 Phe Tyr Pro Ile Tyr Leu Leu Ile Leu Leu Ile Trp Arg Glu Arg Arg  
 325 330 335  
 Asp Glu Val Arg Cys Ala Glu Lys Tyr Lys Glu Ile Trp Ala Glu Tyr  
 340 345 350  
 Leu Arg Leu Val Pro Trp Arg Ile Leu Pro Tyr Val Tyr  
 355 360 365



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
WO 01/23539 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/82, 15/53, 9/02, 5/10, A01H 5/00
- (21) International Application Number: PCT/US00/26442
- (22) International Filing Date:  
27 September 2000 (27.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/156,820 30 September 1999 (30.09.1999) US
- (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): FAMODU, Omolayo, O. [US/US]; 216 Barrett Run Place, Newark, DE 19702 (US). KINNEY, Anthony, J. [GB/US]; 609 Lore Avenue, Wilmington, DE 19809 (US).
- (54) Agent: LI, Kening; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report

[Continued on next page]

(54) Title: GENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS

Comparison of the Corn, Soybean (2), and Arabidopsis Sterol Delta-14 Reductases

```
p0097.cqrau67ra_fis.PRO  -----MESHVDLGFLLQALTPSWNSVPLLVG-----
src3c.pk009.c1_fis.PRO  M-----MESHVDLGFLLQALTPSWNSVPLLVG-----
ssm.pk0031.d12_fis.PRO  M-----MESHVDLGFLLQALTPSWNSVPLLVG-----
8917585_(Arabidopsis).PRO M-----DLGVLLPSL-----QSVYVLFV-----

p0097.cqrau67ra_fis.PRO  -----PRVR-----KNKVELSLLSGLANLC-
src3c.pk009.c1_fis.PRO  -----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLLVALLGIGA
ssm.pk0031.d12_fis.PRO  -----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLLVALLGIGA
8917585_(Arabidopsis).PRO -----YFVYLAVAGEILPGKVIKRVLLSDGSQLRYRCNGLLALILLVAILGICA

p0097.cqrau67ra_fis.PRO  -----KMGFVSPT-----AISDRGLELLSTTFAFSFLVTLILHFGCKSQSKGSS--LKPH-LSG
src3c.pk009.c1_fis.PRO  KMGFVSPT-----AISDRGLELLSTTFAFSFLVTLILHFGCKSQSKGSS--LKPH-LSG
ssm.pk0031.d12_fis.PRO  KMGFVSPT-----AISDRGLELLSTTFAFSFLVTLILHFGCKSQSKGSS--LKPH-LSG
8917585_(Arabidopsis).PRO KMGFVSPT-----VADRGLELLSATFIFCVLVTILALYVTRSSSNKGSS--LKPH-VSG

p0097.cqrau67ra_fis.PRO  -----NLHIDWNFGIQLNPQFMG-IDLKFF--VRAGMMGWLLINLSILMKSQ--DGTLSQSMILY
src3c.pk009.c1_fis.PRO  NLHIDWNFGIQLNPQFMG-IDLKFF--VRAGMMGWLLINLSILMKSQ--DGTLSQSMILY
ssm.pk0031.d12_fis.PRO  NLHIDWNFGIQLNPQFMG-IDLKFF--VRAGMMGWLLINLSILMKSQ--DGTLSQSMILY
8917585_(Arabidopsis).PRO NLHIDWNFGIQLNPQFMG-IDLKFF--VRAGMMGWLLINLSILAKSVQ--DGTLSQSMILY

p0097.cqrau67ra_fis.PRO  -----QLFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLVWIPFSPISQGNWLLMNSVELT
src3c.pk009.c1_fis.PRO  QLFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLVWIPFSPISQGNWLLMNSVELT
ssm.pk0031.d12_fis.PRO  QLFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLVWIPFSPISQGNWLLMNSVELT
8917585_(Arabidopsis).PRO QIPFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLVWIPFSPISQGNWLLHKNVELT

p0097.cqrau67ra_fis.PRO  -----IFLIGYLVFRGANKQKHVFKKPKAPINGKPPKVV--GGKLLASGYWGIA
src3c.pk009.c1_fis.PRO  PAAIVANCFVFLIGYVFRGANKQKHVFKKPKAPINGKPPKVI--GGKLLASGYWGIA
ssm.pk0031.d12_fis.PRO  PAAIVANCFVFLIGYVFRGANKQKHVFKKPKAPINGKPPKVI--GGKLLASGYWGIA
8917585_(Arabidopsis).PRO VPAIVVNCLVFLIGYVFRGANKQKHVFKKPKAPINGKPPKVV--GGKLLVSGYWGIA
```

(57) Abstract: This invention relates to an isolated nucleic acid fragment encoding a sterol delta-14 reductase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the sterol delta-14 reductase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the sterol delta-14 reductase in a transformed host cell.

WO 01/23539 A3



WO 01/23539 A3



**(88) Date of publication of the international search report:**  
7 March 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



# INTERNATIONAL SEARCH REPORT

Application No  
PCT/US 00/26442

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/82 C12N15/53 C12N9/02 C12N5/10 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, WPI Data, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 48793 A (GEN HOSPITAL CORP) 24 December 1997 (1997-12-24) the whole document	1-26
A	EP 0 644 268 A (AMERICAN CYANAMID CO) 22 March 1995 (1995-03-22) the whole document	
A	WO 98 45457 A (MONSANTO CO) 15 October 1998 (1998-10-15) page 9	
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

9 May 2001

Date of mailing of the international search report

25/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

4

5

6

7



INTERNAL SEARCH REPORT

International Application No

PCT/US 00/26442

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P.X	<p>SCHRICK KATHRIN ET AL: "FACKEL is a sterol C-14 reductase required for organized cell division and expansion in Arabidopsis embryogenesis."  GENES &amp; DEVELOPMENT,  vol. 14, no. 12,  15 June 2000 (2000-06-15), pages  1471-1484, XP002166945  ISSN: 0890-9369  the whole document</p>	10
P.X	<p>JANG JYAN-CHYUN ET AL: "A critical role of sterols in embryonic patterning and meristem programming revealed by the fackel mutants of Arabidopsis thaliana."  GENES &amp; DEVELOPMENT,  vol. 14, no. 12,  15 June 2000 (2000-06-15), pages  1485-1497, XP002166946  ISSN: 0890-9369  the whole document</p>	10



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26 partially

Polynucleotide encoding a polypeptide of at least 126 amino acids having a sequence identity of at least 50%, 85%, 90% or 95% to SEQID2 or encoding a polypeptide of at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 4 and 8; the polynucleotide comprising the nucleotide sequences of SEQIDs 1,3 or 7; a nucleic acid molecule hybridizing to said polynucleotides; the recombinant expression of the same in host cells; a method for transforming a cell with said polynucleotides; a method for producing a transgenic plant by transforming the plant with said polynucleotides; an isolated polypeptide of at least 126 amino acids having a sequence identity of at least 50%, 85%, 90% or 95% to SEQID2 or encoding a polypeptide of at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 4 and 8; a method for altering the level of sterol delta-14 reductase expression in a host cell by transforming the cell with said polynucleotides.

2. Claims: 1-26 partially

Polynucleotide encoding a polypeptide of at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 6; the polynucleotide comprising the nucleotide sequence of SEQIDs 5; a nucleic acid molecule hybridizing to said polynucleotide; the recombinant expression of the same in host cells; a method for transforming a cell with said polynucleotide; a method for producing a transgenic plant by transforming the plant with said polynucleotide; an isolated polypeptide at least 369 amino acids having a sequence identity of at least 82%, 85%, 90% or 95% to SEQIDs 6; a method for altering the level of sterol delta-14 reductase expression in a host cell by transforming the cell with said polynucleotide.

1

2

3

4

5

6

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claim 8 was read as referring to a polypeptide that is a sterol delta-14 reductase.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/26442

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9748793	A	24-12-1997	AU 3493997 A EP 0954568 A	07-01-1998 10-11-1999
EP 0644268	A	22-03-1995	US 5591576 A	07-01-1997
WO 9845457	A	15-10-1998	AU 724046 B AU 5709998 A BR 9714439 A CN 1247569 A EP 0958370 A	07-09-2000 30-10-1998 21-03-2000 15-03-2000 24-11-1999





From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

RECEIVED

JAN 02 2002

PCT  
PATENT RECORDS  
CENTER

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

To:

LI, Kening  
E.I. DUPONT DE NEMOURS AND COMPANY  
Legal Patent Records Center  
1007 Market Street  
Wilmington, Delaware 19899  
ETATS-UNIS D'AMERIQUE

Date of mailing  
(day/month/year) 18.12.2001

Applicant's or agent's file reference  
BB1395PCT

IMPORTANT NOTIFICATION

International application No.  
PCT/US00/26442

International filing date (day/month/year)  
27/09/2000

Priority date (day/month/year)  
30/09/1999

Applicant  
E.I. DU PONT DE NEMOURS AND COMPANY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Hingel, W

Tel. +49 89 2399-8717



30 MR 2002



# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>BB1395PCT</b>	<div style="display: flex; justify-content: space-between;"> <div> <b>FOR FURTHER ACTION</b> </div> <div>           See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)         </div> </div>	
International application No. <b>PCT/US00/26442</b>	International filing date (day/month/year) <b>27/09/2000</b>	Priority date (day/month/year) <b>30/09/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>C12N15/00</b>		
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of    sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I    <input checked="" type="checkbox"/> Basis of the report</li> <li>II   <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV   <input checked="" type="checkbox"/> Lack of unity of invention</li> <li>V    <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI   <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>		
Date of submission of the demand  <b>12/04/2001</b>	Date of completion of this report  <b>18.12.2001</b>	
Name and mailing address of the international preliminary examining authority:  <div style="display: flex; align-items: center;"> <div>             European Patent Office              D-80298 Munich              Tel. +49 89 2399 - 0 Tx: 523656 epmu d              Fax: +49 89 2399 - 4465           </div> </div>	Authorized officer  <b>Armandola, E</b>  Telephone No. +49 89 2399 7493	





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/26442

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-32 as originally filed

**Claims, No.:**

1-26 as originally filed

**Drawings, sheets:**

1/2-2/2 as originally filed

**Sequence listing part of the description, pages:**

1-9, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/26442

- ☐ the description,      pages:  
☐ the claims,      Nos.:  
☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.  
☐ paid additional fees.  
☐ paid additional fees under protest.  
☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.  
☐ not complied with for the following reasons:

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☒ all parts.  
☐ the parts relating to claims Nos. .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)      Yes:      Claims





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/26442

	No:	Claims	1, 8-18, 23-25
Inventive step (IS)	Yes:	Claims	
	No:	Claims	2-7, 19-22, 26
Industrial applicability (IA)	Yes:	Claims	1-26
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/26442

**Re Item IV**

**Lack of unity of invention**

The IPEA agrees with the objection made by the International Search Authority about the lack of unity of the present application. The reasons for the lack of unity are as follows:

polynucleotides encoding plant sterol reductases and their uses were known (see WO9748793). The problem to be solved by the present application can be seen as the provision of further polypeptides encoding sterol reductases. The only common special technical features shared by the provided solutions (polynucleotides and polypeptides identified by SEQ. ID. NO: 1-8) is their belonging to the sterol reductase class of enzymes. These enzymes were, however, known. Therefore, no single general inventive concept (Rule 13.1 PCT) can be recognized as linking the claimed proteins.

However, as the ISA has provided a complete search report, the IPEA has decided not to invite the applicant to pay additional fees and to carry out the examination for all inventions.

The objection to lack of unity will, however, be prosecuted during regional phase examination at the EPO.

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document:

D1: WO 97 48793 A (GEN HOSPITAL CORP) 24 December 1997 (1997-12-24)

Novelty and Inventive step (Art. 33(2) (3) PCT)

i) Claims 1, 8-18 and 23-25 cannot be considered novel in view of document D1 which discloses plant sterol reductases and their uses. In particular SEQ. ID. NO: 2 of D1 displays 64.3% identity to SEQ. ID. NO: 2 of the application. Cells containing the polynucleotide encoding the C-14 sterol reductase, methods of transforming cells, isolating the C-14 sterol reductase and of producing transgenic plants containing constructs



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/26442

encoding it are also disclosed, as well as methods of altering the levels of the enzyme in plants.

It should be noted that even if novelty were re-established by increasing the percent identity required in claim 1 a), the claims would not be considered inventive. The problem to be solved by the present claims could be seen as that of providing an alternative C-14 sterol reductase (namely one derived from another plant species); as D1 provides an incentive and the means for doing this (see e.g. claim 25), the skilled person would not have needed to exercise inventive skill to obtain such an additional C-14 sterol reductase. For the same reasons claims 2-7, 19-22 and 26 cannot be considered inventive.

**Re Item VII**

**Certain defects in the international application**

Claim 8 is incomplete.

**Re Item VIII**

**Certain observations on the international application**

Clarity (Art. 6 PCT)

i) Claims 1-4 and 18-21 contain the indication of a percent identity that the claimed polynucleotide should display, but no functional feature is given which may identify the polynucleotide precisely. Polynucleotides which do not encode a protein according to the invention might also fall under the scope of the claims. The claims are, therefore considered unclear.

ii) In claim 6 a fragment is claimed for which no functional limitation is given. The claim is considered to be vague and unclear as it leaves the reader in doubt as to how the fragment of 125 nucleotides should be chosen within the SEQ. ID. NO. indicated.

